Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
PZ HTL SA
GLOBETECH PUBLISHING

siRNA Screen Identifies Potential Cystic Fibrosis Drug Target

By BiotechDaily International staff writers
Posted on 26 Sep 2013
Image: Inhibiting DGKi reduces ENaC activity, reversing the effects of cystic fibrosis. In this assay, the green glow dims more in cells with active ENaC (bottom), so the scientists screened for cases where the cells’ glow barely changed (top) (Photo courtesy of Dr. Rainer Pepperkok, European Molecular Biology Laboratory).
Image: Inhibiting DGKi reduces ENaC activity, reversing the effects of cystic fibrosis. In this assay, the green glow dims more in cells with active ENaC (bottom), so the scientists screened for cases where the cells’ glow barely changed (top) (Photo courtesy of Dr. Rainer Pepperkok, European Molecular Biology Laboratory).
A large-scale screen combining high-content live-cell microscopy and small interfering RNAs (siRNAs) in human airway epithelial cells from patients with cystic fibrosis (CF) has pinpointed a promising target for drug treatment.

Cystic fibrosis is an inherited disease caused by a mutation in the CFTR (cystic fibrosis transmembrane conductance regulator) gene that affects the body's ability to move salt and water in and out of cells. CTFR codes for an ABC transporter-class ion channel, ENaC, which transports chloride and thiocyanate ions across epithelial cell membranes. Mutations of the CFTR gene disrupt the functioning of ENaC chloride ion channels in these cell membranes, leading to cystic fibrosis.

All disease-causing mutations in the CFTR gene prevent the channel from functioning properly, leading to a blockage of the movement of salt and water into and out of cells. As a result of this blockage, cells that line the passageways of the lungs, pancreas, and other organs produce abnormally thick, sticky mucus. This mucus obstructs the airways and glands, causing the characteristic signs and symptoms of cystic fibrosis. While thin mucus can be removed by cilia, thick mucus cannot be removed by cilia, so it traps bacteria that give rise to chronic infections. The only drug currently available that directly counteracts a cystic fibrosis-related mutation only works on the 3% of patients that carry one specific mutation out of the almost 2000 CFTR mutations detected so far.

Investigators at the European Molecular Biology Laboratory (Heidelberg, Germany) and their colleagues at the University of Lisbon (Portugal) sought to develop a global understanding of molecular regulators of ENaC traffic and function and to identify candidate CF drug targets. To this end, they performed a large-scale screen combining high-content live-cell microscopy and siRNAs in human airway epithelial cells.

A study published in the September 12, 2013, online edition of the journal Cell revealed that the investigators screened over 6,000 genes and identified over 1,500 candidates, evenly divided between channel inhibitors and activators.

Genes in the phosphatidylinositol pathway were enriched on the primary candidate list, and these, along with other ENaC activators, were examined further with secondary siRNA validation. Subsequent detailed investigation revealed ciliary neurotrophic factor receptor (CNTFR) as an ENaC modulator and showed that inhibition of DGKi (diacylglycerol kinase, iota), a protein involved in phosphatidylinositol biphosphate (PiP2) metabolism, downgraded ENaC activity, leading to normalization of both Na+ and fluid absorption in CF airways to non-CF levels in primary human lung cells from CF patients.

“Inhibiting DGKi seems to reverse the effects of cystic fibrosis, but not block ENaC completely,” said senior author Dr. Margarida Amaral, professor of chemistry and biochemistry at the University of Lisbon, “indeed, inhibiting DGKi reduces ENaC activity enough for cells to go back to normal, but not so much that they cause other problems, like pulmonary edema.”

Related Links:

European Molecular Biology Laboratory
University of Lisbon



Channels

Drug Discovery

view channel

Retinoic Acid Prevents Precancerous Breast Cells from Progressing to Full-Blown Cancer

Retinoic acid, a derivative of vitamin A, was found to prevent pre-cancerous breast cells from progressing to full-blown cancer but did not have any effect on breast tumor cells. Investigators at Thomas Jefferson University (Philadelphia, PA, USA) worked with a novel breast cancer model that had been developed by treating... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more

Business

view channel

Analytical Sciences Trade Fair Declared a Rousing Success

Organizers of this year's 24th "analytica" biosciences trade fair have reported significant increases in both the number of visitors and exhibitors compared to the 2012 event. The analytica trade fair for laboratory technology, analysis, and biotechnology has been held at the Munich (Germany) Trade Fair Center every... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.